SCHEMBL6748435

SCHEMBL6748435

Clc1ccnc2oc(-c3ccccc3)cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
KDM4E B2RXH2 4/20 0.49
ALDH1A1 P00352 4/20 0.49
NPC1 O15118 3/20 0.49
THRB P10828 2/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
CYP1A2 P05177 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
EGFR P00533 4/20 0.46
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MCHR1 Q99705 1/20 0.45
GSK3B P49841 2/20 0.44
KDR P35968 2/20 0.44
HSP90AA1 P07900 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL759984 0.77 HPGD (0.60) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL722060 0.73 CYP1A1 (0.47) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL1644987 0.72 CYP1B1 (0.63) HPGDKDM4EALDH1A1NPC1TSHR
SCHEMBL12663309 0.72 HTR2C (0.40) MEN1KMT2AKDM4EALDH1A1NPC1
SCHEMBL3574183 0.70 PTGES (0.51) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL27906923 0.70 GABRP (0.56) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL1784311 0.70 HPGD (0.60) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL12410512 0.70 HPGD (0.60) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL30361969 0.70 HPGD (0.60) HPGDMEN1KMT2AKDM4EALDH1A1
SCHEMBL1789896 0.68 HPGD (0.49) HPGDMEN1KMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324222-B2 Cyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-12-04 US disclosed
US-8183246-B2 Acyclically substituted furopyrimidine derivatives and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-05-22 US disclosed
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2011-05-26 US disclosed
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof BAYER HEALTHCARE AG (DE) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124665-A1 Novel, Cyclically Substituted Furopyrimidine Derivatives and Use Thereof DPYD, TK2, TPMT HPGD 75/4885MEN1 3301/4885KMT2A 4121/4885
US-20090318475-A1 Novel, Acyclically Substituted Furopyrimidine Derivatives and Use Thereof DPYD, PNPO, TPMT HPGD 75/4885MEN1 2837/4885KMT2A 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.